ER、PR、Survivin与分化型甲状腺癌的表达及临床意义的开题报告

精品文档---下载后可任意编辑ER、PR、Survivin 与分化型甲状腺癌的表达及临床意义的开题报告Abstract:Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy and its incidence has been increasing over the past few decades. The aim of this study is to investigate the expression of ER, PR, and Survivin in DTC and their association with clinicopathological features.Introduction:DTC is classified into two major subtypes, namely papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). Although generally considered to have good prognosis, there are a significant number of patients who suffer recurrence and distant metastasis. Therefore, identifying molecular markers associated with DTC progression and prognosis will improve patient management.Methods:We will collect DTC tissues from patients who underwent surgery at our hospital for this study. Immunohistochemical staining will be performed to detect the expression of ER, PR, and Survivin in DTC tissues. The clinical information of patients will also be collected to analyze the association between these markers and clinicopathological characteristics.Expected results:We expect to find differential expression of ER, PR, and Survivin in DTC tissues, which may provide novel prognostic markers for DTC. We will also correlate their expression with patient demographics, tumor features, and clinical outcomes.Conclusion:This study will provide important insights into the expression and clinical significance of ER, PR, and Survivin in DTC. The findings will lay a foundation for future studies investigating the mechanisms of these molecules in DTC development and progression. Ultimately, our results may contribute to the development of new therapeutic targets for DTC patients.